RX001 / GeneCraft - LARVOL DELTA

A first-in-human, intra-tumoral AAV2-RUNX3 gene therapy (RX001) for advanced KRAS-mutant NSCLC (NCT06934590): Phase 1 trial in progress (AACR 2026) - P1 | "Abstract is embargoed at this time."

First-in-human • Gene therapy • Metastases • P1 data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • KRAS • RUNX3

Evaluate Safety and Tolerability of RX001 in Patients With KRAS Mutant Advanced NSCLC (clinicaltrials.gov) - P1 | N=18 | Not yet recruiting | Sponsor: GeneCraft Inc.

New P1 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • KRAS

GenScript ProBio Signs MOU to Form Strategic Partnership with GeneCraft To Development and Production of New AAV gene therapies (PRNewswire-Asia) - "GenScript ProBio...and GeneCraft...announced that they had entered into a strategic partnership MOU concerning the development and production of a new drugs needed for RX001....GenScript ProBio and GeneCraft are in the process of signing a contract for plasmid and AAV development and production for the GeneCraft's own new drug candidate Pan-KRAS non-small cell lung cancer anti-cancer gene therapy (RX001) developed as a new drug. With this agreement, GenScript ProBio has become a global partner that can support GeneCraft's various gene therapy pipelines."

Licensing / partnership • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Thoracic Cancer